Elecoglipron compared with semaglutide for adults with type 2 diabetes
Tests elecoglipron against semaglutide in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
Key facts
- Where
- Guelph, Montreal, Saint-Charles-Borromée, Sarnia, Scarborough Village, Stouffville, Toronto, and Vancouver, CanadaSee the 8 sites
- Phase
- Phase 3
Where in Canada
- GuelphGuelph, CanadaTaking people
- MontrealMontreal, CanadaTaking people
- Saint-Charles-BorroméeSaint-Charles-Borromée, CanadaTaking people
- SarniaSarnia, CanadaTaking people
- Scarborough VillageScarborough Village, CanadaTaking people
- StouffvilleStouffville, CanadaTaking people
- TorontoToronto, CanadaTaking people
- VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07662213EU 2025-523933-24-00
- Record updated
- 22 October 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).Read full original descriptionShow less
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
Inclusion: Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening; T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s); HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol); Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors; Body mass index (BMI) of ≥ 23 kg/m2 at screening; Stable body weight (self-reported or documented) for 90 days prior to screening.
Exclusion: Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma; Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying; History of acute or chronic pancreatitis; Severe congestive heart failure (NYHA IV); History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.